Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
NCT ID: NCT05254314
Last Updated: 2025-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
100 participants
INTERVENTIONAL
2022-10-11
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
NCT04251156
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
NCT03552757
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
NCT06041217
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
NCT04074161
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
NCT02453711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Drug (Semaglutide)
Semaglutide 2.4mg once weekly
Semaglutide Pen Injector 2.4mg weekly
Once weekly subcutaneous injection
Placebo
Placebo 2.4mg once weekly
Placebo
Once weekly subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Semaglutide Pen Injector 2.4mg weekly
Once weekly subcutaneous injection
Placebo
Once weekly subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males and females age 18 or older
3. Obesity defined as body mass index (BMI) \>=30, or \>=27 in the setting of \>=1 weight-related comorbidity:
* clinically documented hypertension (\>130 mmHg systolic or \>85 mmHg diastolic or treatment) in the prior year or during run-in
* clinically documented dyslipidemia (Triglycerides ш 150 mg/dl, HDL \<40 mg/dl in males or \<50 mg/dl in females, \>=130 mg/dl or treatment) in the prior year or during run-in
* current obstructive sleep apnea treatment
* documented pre-diabetes defined by A1c 5.7-\<6.5 in the prior year or during run-in
* clinically documented cardiovascular disease
4. History of physician-diagnosed asthma
5. Persistent Asthma as determined by the requirement of at least medium-dose daily inhaled corticosteroid or more
6. Symptomatic asthma with an ACQ-6 score \>=1.5 at enrollment and at the time of randomization
7. Patient report of stable asthma controller regimen for the prior 8 weeks
8. Evidence of bronchodilator responsiveness (\>=12% and at least 200 mL increase in FEV1) or airway hyperresponsiveness with a Methacholine PC20 \<=16 mg/mL or PD20 \<=400 mcg in the prior year
9. Female subjects of childbearing potential must have a negative pregnancy test upon study entry
10. Female subjects of childbearing potential must agree to use a highly effective birth control method (e.g. hormonal, surgical or abstinence) for the duration of the study
Exclusion Criteria
1. Inability or unwillingness of a subject to give written informed consent or comply with the study protocol
2. Diagnosis of type I or type II diabetes mellitus (DM) or HbA1c ≥6.5 on screening labs
3. Use of \>8 puffs/inhalations of short-acting bronchodilators most days in the previous week (i.e. answer to question #6 on ACQ-6 = 4, 5, or 6)
4. Oxygen saturation \< 94% on room air
5. Patient-reported Tobacco, e-cigarette, or smoked marijuana use within 12 months#, or \>10 pack-years of use\*
* Can still be enrolled if ≥40 years old, smoked \<20 pack years, none within 12 months#, and demonstrate a post-bronchodilator FEV1/FVC ratio of \>0.7 or a DLCO z-score of -1.645 or greater (or the equivalent ≥ 75% of predicted) documented in prior 12 months or during run-in
\* Smoking equivalent pack years. One pack of cigarettes a day for 1 year is equivalent to:
* 1 cigar or pipe per day for 1 year
* Smoked hookah or shisha =1 session per day for 1 year
* Vaped e-cigarettes =0.5 mLs e-liquid per day for 1 year, or =1 cartridge/tank/pod per day for 1 year
* 1 use of inhaled marijuana per day for 1 year
#Use of any inhalant \>1 time weekly in the past year is considered use within 12 months.
* Active smoking of conventional tobacco, inhaling of marijuana or other drugs, or vaping of e-cigarettes or vape pods \>1 time per week in the past year.
* Any form of tobacco qualifies, such as: 1 cigarette, 1 hookah or shisha sessions, 1 cigar, 1 pipe, etc.
* Any electronic (e)-device included: e-cigarette e-cig, mod, vape pen, JUUL, e-cigar, e-hookah, e-pipe, vape pods, etc.
* Any form of inhaled marijuana, including smoking marijuana leaves or inhaling THC via e-cigarette or device
6. Pregnancy by urine testing, current lactation, or plans to become pregnant during the study period
7. Pharmaceutical weight loss treatment for \>7 days in the prior 90 days at enrollment
8. Previous surgical weight loss treatment. Can still be enrolled if surgery \> 5 years ago and evidence of stable or increasing weight in the prior 3-12 months.
9. Personal history of pancreatitis as determined by history
10. Personal or family history of medullary thyroid cancer by history or multiple endocrine neoplasia syndrome type 2
11. Personal history of gallstone disease without previous cholecystectomy
12. Personal history of gastroparesis
13. Personal history of hypersensitivity to semaglutide
14. Personal history of hypersensitivity to local amide type (ex. Lidocaine) anesthetics
15. Use of antidiabetic agent, other than metformin, including GLP-1R agonist in the previous 90 days. Metformin is allowed provided the dose has been stable in the 90 days prior to screening and will remain stable for the duration of the trial.
16. Use of systemic glucocorticoids in the past 28 days
17. Use of monoclonal antibody for the treatment of asthma in the past 120 days
18. Myocardial infarction, unstable angina, stroke, or heart failure (NYHA class II) within 1 year by history
19. Patient report and confirmed by review of historical diagnostic testing by study physician of other physician-diagnosed chronic respiratory diseases: COPD, cystic fibrosis, pulmonary hypertension, interstitial lung disease, sarcoidosis, bronchiectasis
20. History of physician-diagnosed immune deficiency.
21. History of physician-diagnosed malignancy (other than excised non-melanoma skin cancer) in the past 5 years.
22. Current uncontrolled hypertension (systolic \>150, diastolic \>90) or untreated hyperthyroidism
23. Current, diagnosed or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.
24. Use of investigational drugs within 20 weeks of participation, other than vaccines and/or treatments for SARS-CoV-2 authorized for emergency use
25. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
At randomization:
26. Screening creatinine elevation with EGFR\<30 ml/min/1.73 m2 collected at visit 1a
27. Compliance to baseline asthma inhaler therapy of \<80% during run-in, at the time of randomization.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Vanderbilt University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Katherine Cahill, MD
Medical Director of Asthma Clinical Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katherine Cahill, MD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Study Approved Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAIT-U01-VAN-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.